Dat

Paragon Protocol: the Hidden Security Threats of NFT Asset Stored Off-chain

Friday, June 11, 2021 - 9:15am

In this regard, Paragon, a protocol-level project aimed at activating the value of high-quality NFT assets, puts forward a constructive plan for how to ensure the security of NFT assets.

Key Points: 
  • In this regard, Paragon, a protocol-level project aimed at activating the value of high-quality NFT assets, puts forward a constructive plan for how to ensure the security of NFT assets.
  • Paragon emphasizes that IPFS data on the chain can ensure the security of NFT assets.
  • In this way, the user's NFT asset data can be protected from the hidden dangers of asset security caused by problems such as Internet failure.
  • The IPFS protocol can protect NFT assets in an encrypted manner, and the form of decentralized storage ensures the security of NFT artworks for each user.

Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes

Wednesday, April 28, 2021 - 12:00pm

In parallel, we are continuing to evaluate less frequent dosing regimens than our current weekly dosing.

Key Points: 
  • In parallel, we are continuing to evaluate less frequent dosing regimens than our current weekly dosing.
  • \xe2\x80\x9cBob has played a pivotal role in transitioning the CEO leadership in 2019, and positioning the company for our subsequent transformation program in 2020.
  • Trillium would not be where it is today without Bob\xe2\x80\x99s leadership, hands-on contributions and personal sacrifices.
  • Pharmacokinetic data demonstrated dose-proportional increases in drug exposure between 8 and 18 mg/kg, and support evaluating less frequent dosing.

Lime Partners With Everlaw to Streamline eDiscovery

Tuesday, December 1, 2020 - 3:00pm

Lime will use Everlaw's cloud platform to maintain greater autonomy over litigation workflows and streamline projects, all while securing sensitive data.

Key Points: 
  • Lime will use Everlaw's cloud platform to maintain greater autonomy over litigation workflows and streamline projects, all while securing sensitive data.
  • Historically, outside counsel and in-house technology have served as bottlenecks, hindering the ability to seamlessly track workflows and securely collaborate among multiple legal partners.
  • "Everlaw has changed the game for how we analyze data and collaborate on legal matters in today's digital world," said Jesse Murray, Head of Trust and Safety at Lime.
  • As the global leader in micromobility, Lime partners with cities to deploy electric bikes and scooters enabled with GPS and self-activating locks.

Innate Pharma Launches HopeConnectLearn: A New Online Resource for Hairy Cell Leukemia Patients

Thursday, November 5, 2020 - 1:00pm

ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced the launch of HopeConnectLearn, a new online resource for the hairy cell leukemia community.

Key Points: 
  • ROCKVILLE, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today announced the launch of HopeConnectLearn, a new online resource for the hairy cell leukemia community.
  • HopeConnectLearn provides education and connection for patients and their caregivers across the spectrum of disease, from a new diagnosis to relapse or refractory experiences.
  • About 40 percent of patients will relapse in 5-10 years following first treatment.iii_iv
    "When facing a rare disease like hairy cell leukemia, patients derive hope from hearing directly from other patients and learning about their experiences," said Anna Lambertson, Executive Director of the Hairy Cell Leukemia Foundation.
  • Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

NuCana Presents Three Posters at the ESMO Virtual Congress 2020

Monday, September 21, 2020 - 9:02pm

EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), announced data from the ongoing NUC-3373 and NUC-7738 clinical programs, as well as a review of the ongoing Acelarin Phase III study, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

Key Points: 
  • EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), announced data from the ongoing NUC-3373 and NUC-7738 clinical programs, as well as a review of the ongoing Acelarin Phase III study, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.
  • NuCana believes these data support the potential of NUC-3373 to improve progression-free survival in patients who had relapsed or were refractory to prior 5-FU containing regimens.
  • NuCana also believes these data show NUC-3373s potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen as compared to 5-FU.
  • Additionally, interim data from two case studies showed the significant reductions in tumor volume were maintained over time in these patients.

Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level

Thursday, July 30, 2020 - 12:00pm

After experiencing a temporary slow-down in patient enrollment due to Covid-19, we are now moving ahead with the 2.0 mg/kg dose level, and anticipate dosing the first patient in early August 2020.

Key Points: 
  • After experiencing a temporary slow-down in patient enrollment due to Covid-19, we are now moving ahead with the 2.0 mg/kg dose level, and anticipate dosing the first patient in early August 2020.
  • 15 relapsed/refractory CTCL patients have been enrolled in the first 4 cohorts, and were treated with TTI-621 monotherapy at doses up to 1.4 mg/kg.
  • Dose limiting toxicity (DLT) evaluation of Cohort 4 (1.4 mg/kg dose level) has been successfully completed and dose escalation is now continuing at 2.0 mg/kg.
  • Trillium intends to provide an update on its TTI-621 and TTI-622 studies at the American Society for Hematology Annual Meeting in December 2020.

Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma

Monday, July 20, 2020 - 8:00am

The study was designed to recruit a total of 15 patients across 4 doses of 0.5, 1, 2, and 4 mg/kg for intravenous weekly dosing.

Key Points: 
  • The study was designed to recruit a total of 15 patients across 4 doses of 0.5, 1, 2, and 4 mg/kg for intravenous weekly dosing.
  • The primary endpoint was overall safety after 4 weeks of treatment.There was a 3-month treatment extension to further evaluate safety and clinical response.
  • BNZ-1 is currently under investigation in a phase 1/2 clinical trial for refractory Cutaneous T-Cell Lymphoma (rCTCL) and Large Granular Lymphocyte (LGL) Leukemia ( www.clinicaltrials.gov identifier: NCT03239392).
  • Bioniz is developing a robust pipeline of product candidates in multiple autoimmune and oncology indications.

Kiadis Pharma announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at the 25th Congress of the European Hematology Association

Thursday, May 14, 2020 - 2:15pm

The Kiadis Pharma off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.

Key Points: 
  • The Kiadis Pharma off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.
  • Kiadis Pharma is clinically developing K-NK003 for the treatment of relapse/refractory acute myeloid leukemia.
  • Founded in 1997, Kiadis Pharma is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

DAT Solutions Names Former FedEx Data Scientist Ken Adamo as Chief of Analytics

Monday, December 16, 2019 - 1:00pm

PORTLAND, Ore., Dec. 16, 2019 (GLOBE NEWSWIRE) -- DAT Solutions announced today that Ken Adamo former Manager of Decision Science and Innovation at FedEx Custom Critical has joined the company as Chief of Analytics, effective immediately.

Key Points: 
  • PORTLAND, Ore., Dec. 16, 2019 (GLOBE NEWSWIRE) -- DAT Solutions announced today that Ken Adamo former Manager of Decision Science and Innovation at FedEx Custom Critical has joined the company as Chief of Analytics, effective immediately.
  • Prior to joining DAT, Adamo developed rate forecasting models and advanced pricing principles for FedEx that utilized DAT RateView and DAT Data Analytics.
  • As Chief of Analytics, Adamo will spearhead the company's vision and strategy for data science, drawing upon his experience at FedEx.
  • At FedEx, my team relied on market data from DAT to help develop models and make recommendations across the enterprise, explained Adamo.

MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting

Monday, December 9, 2019 - 8:05pm

Furthermore, the same gene signature was associated with patients more likely to respond to flotetuzumab, supporting the mechanism being exploited by this molecule.

Key Points: 
  • Furthermore, the same gene signature was associated with patients more likely to respond to flotetuzumab, supporting the mechanism being exploited by this molecule.
  • Flotetuzumab, an Investigational CD123 x CD3 Bispecific DART Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
    Abstract #460: Vadakekolathu, et al.
  • ET to review the flotetuzumab data presented at the ASH Annual Meeting and discuss ongoing clinical development plans.
  • Approximately 40-50% of newly diagnosed patients fail to achieve a complete remission with intensive induction therapy (primary induction failure) or experience disease recurrence after a short remission duration (